Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Rituximab Treatment and Improvement of Health-Related Quality of Life in Patients With Pemphigus Publisher Pubmed



Aryanian Z1, 2 ; Balighi K1, 3 ; Nassimi M1, 3 ; Hatami P1 ; Shahandashti MI1 ; Goodarzi A1, 4 ; Etesami I1, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. The Autoimmune Bullous Disease Research Center, Razi Hospital, Tehran University of Medical Sciences, Iran
  2. 2. The Department of Dermatology, Babol University of Medical Sciences, Iran
  3. 3. The Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Iran
  4. 4. The Department of Dermatology, School of Medicine, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran

Source: Cutis Published:2023


Abstract

Pemphigus is an autoimmune blistering disease that can negatively affect patients’ lives. Assessing the impact of treatment from a patient’s perspective using outcome assessment measures is important and relevant in trials of new pemphigus treatments including rituximab (RTX). We sought to evaluate the effect of RTX on health-related quality of life (HRQOL) in pemphigus patients and peruse the clinical relevance of the patient-reported outcomes. A retrospective cross-sectional study was designed with 96 pemphigus patients given RTX either 3 months earlier or in the last 2 weeks. The treatment was evaluated by patients using HRQOL assessment tools: 36-Item Short Form Survey (SF-36) and Dermatology Life Quality Index (DLQI). Another patient-reported assessment was the patient global assessment (PGA). We found that RTX administration in pemphigus patients led to rapid and notable improvement in HRQOL and patient-assessed measures. © 2023 Quadrant Healthcom Inc.. All rights reserved.
Related Docs
View other Related Docs
1. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
2. Rituximab Exhibits a Better Safety Profile When Used As a First Line of Treatment for Pemphigus Vulgaris: A Retrospective Study, International Immunopharmacology (2021)
3. Family Impact of Pemphigus Disease in an Iranian Population Using the Family Dermatology Life Quality Index, International Journal of Women's Dermatology (2020)
4. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
5. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
6. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
7. Assessment of Health-Related Quality of Life in Patients With Frontal Fibrosing Alopecia, Journal of Cosmetic Dermatology (2022)
8. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (17)
Kamran Balighi (14)
Other Related Docs
9. Characteristics Associated With Quality of Life in the Early Stages of Mycosis Fungoides, Caspian Journal of Internal Medicine (2023)
10. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
11. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
12. Illness Perception of Patients With Pemphigus Vulgaris, International Journal of Women's Dermatology (2019)
13. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
14. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
15. Autoimmune Bullous Disease Quality of Life (Abqol) Questionnaire: Validation of the Translated Persian Version in Pemphigus Vulgaris, International Journal of Women's Dermatology (2020)
16. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
17. Rituximab Therapy Improves Recalcitrant Pemphigus Vulgaris, EXCLI Journal (2015)
18. Assessing Quality of Life in Patients With Autoimmune Bullous Diseases Using the Persian Version of Treatment of Autoimmune Bullous Disease Quality of Life Questionnaire Finds Similar Effects in Women As Men, International Journal of Women's Dermatology (2022)
19. Evaluating the Risk-To-Benefit Ratio of Using Cotrimoxazole As a Pneumocystis Pneumonia Preventative Intervention Among Pemphigus Patients Treated With Rituximab: A Retrospective Study With 494 Patients, Dermatologic Therapy (2022)